Journal of Hematology & Oncology is the official journal of the Chinese American Hematologist and Oncologist Network.
Articles
Page 3 of 39
-
Citation: Journal of Hematology & Oncology 2023 16:51
-
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors
QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1), with a shorter elimination half-l...
Citation: Journal of Hematology & Oncology 2023 16:50 -
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study
Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not require immediate ther...
Citation: Journal of Hematology & Oncology 2023 16:49 -
Echinomycin as a promising therapeutic agent against KSHV-related malignancies
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiologic agent of several human cancers, including Kaposi’s sarcoma (KS) and primary effusion lymphoma (PEL), which preferentially arise in immunocompromi...
Citation: Journal of Hematology & Oncology 2023 16:48 -
Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization
COVID-19 inactivated vaccine-induced humoral responses in patients with lung cancer (LCs) to SARS-CoV-2 wild-type (WT) strain and variants BA.4/5 after the primary 2-dose and booster vaccination remained unkno...
Citation: Journal of Hematology & Oncology 2023 16:47 -
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis
Bone metastasis is the leading cause of death in patients with prostate cancer (PCa) and currently has no effective treatment. Disseminated tumor cells in bone marrow often obtain new characteristics to cause ...
Citation: Journal of Hematology & Oncology 2023 16:46 -
The Notch signaling pathway: a potential target for cancer immunotherapy
Dysregulation of the Notch signaling pathway, which is highly conserved across species, can drive aberrant epigenetic modification, transcription, and translation. Defective gene regulation caused by dysregula...
Citation: Journal of Hematology & Oncology 2023 16:45 -
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
Historically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL) experienced poor outcomes with intensive chemotherapy. This mature analysis explores the benefit of the addition of sequential b...
Citation: Journal of Hematology & Oncology 2023 16:44 -
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal
Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop T...
Citation: Journal of Hematology & Oncology 2023 16:43 -
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax combined with azacitidine plus homoharringto...
Citation: Journal of Hematology & Oncology 2023 16:42 -
Retraction Note: miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization
Citation: Journal of Hematology & Oncology 2023 16:41 -
Emerging evidence and treatment paradigm of non-small cell lung cancer
Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unpr...
Citation: Journal of Hematology & Oncology 2023 16:40 -
Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients
Cancer patients, due to their immunocompromised status, are at an increased risk for severe SARS-CoV-2 infection. Since severe SARS-CoV-2 infection causes multiple organ damage through IL-6-mediated inflammati...
Citation: Journal of Hematology & Oncology 2023 16:39 -
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
The advent of immunotherapy has made an indelible mark on the field of cancer therapy, especially the application of immune checkpoint inhibitors in clinical practice. Although immunotherapy has proven its eff...
Citation: Journal of Hematology & Oncology 2023 16:38 -
Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study
Recurrent mutations in TP53, RAS pathway and JAK2 genes were shown to be highly prognostic of allogeneic hematopoietic cell transplant (alloHCT) outcomes in myelodysplastic syndromes (MDS). However, a signific...
Citation: Journal of Hematology & Oncology 2023 16:37 -
The functional and clinical roles of liquid biopsy in patient-derived models
The liquid biopsy includes the detection of circulating tumor cells (CTCs) and CTC clusters in blood, as well as the detection of, cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) and extracellular vesicles...
Citation: Journal of Hematology & Oncology 2023 16:36 -
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
Chimeric antigen receptor (CAR)-NK cell therapy has the advantages of a low incidence of side effects and a low cost. However, the clinical outcomes are not satisfactory due to limited antitumor effects and a ...
Citation: Journal of Hematology & Oncology 2023 16:35 -
Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia
Donor-derived CD7-directed chimeric antigen receptor (CAR) T cells showed feasibility and early efficacy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia (r/r T-ALL), in a previous p...
Citation: Journal of Hematology & Oncology 2023 16:34 -
PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation
In human cells BRAF oncogene is invariably expressed as a mix of two coding transcripts: BRAF-ref and BRAF-X1. These two mRNA isoforms, remarkably different in the sequence and length of their 3′UTRs, are potenti...
Citation: Journal of Hematology & Oncology 2023 16:33 -
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report ...
Citation: Journal of Hematology & Oncology 2023 16:32 -
APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential
Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBECs) are cytosine deaminases involved in innate and adaptive immunity. However, some APOBEC family members can also deaminate host genomes to g...
Citation: Journal of Hematology & Oncology 2023 16:31 -
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia
Cancer cachexia is a deadly wasting syndrome that accompanies various diseases (including ~ 50% of cancers). Clinical studies have established that cachexia is not a nutritional deficiency and is linked to exp...
Citation: Journal of Hematology & Oncology 2023 16:30 -
Recent advances in targeted therapies in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival for younger patients over the last several decades has improved nearly sixfold with the optimization of intensive induct...
Citation: Journal of Hematology & Oncology 2023 16:29 -
Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications
The tumor microenvironment (TME) has been extensively investigated; however, it is complex and remains unclear, especially in elderly patients. Senescence is a cellular response to a variety of stress signals,...
Citation: Journal of Hematology & Oncology 2023 16:28 -
AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears
Acute myeloid leukemia (AML) is a deadly hematological malignancy. Cellular morphology detection of bone marrow smears based on the French–American–British (FAB) classification system remains an essential crit...
Citation: Journal of Hematology & Oncology 2023 16:27 -
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Treatment options specifically for patients with locally advanced pancreatic adenocarcinoma (LAPC) are scare and chemotherapy alone delivers limited efficacy. Immunotherapy and radiotherapy are potential effec...
Citation: Journal of Hematology & Oncology 2023 16:26 -
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
There are situations where non-first-degree (NFD) related donors have to be considered as alternatives to first-degree (FD) related donors for haploidentical hematopoietic cell transplantation (HAPLO). However...
Citation: Journal of Hematology & Oncology 2023 16:25 -
Involvement of inflammasomes in tumor microenvironment and tumor therapies
Inflammasomes are macromolecular platforms formed in response to damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns, whose formation would cause maturation of interleukin-1...
Citation: Journal of Hematology & Oncology 2023 16:24 -
Tumor cell integrin β4 and tumor stroma E-/P-selectin cooperatively regulate tumor growth in vivo
The immunological composition of the tumor microenvironment has a decisive influence on the biological course of cancer and is therefore of profound clinical relevance. In this study, we analyzed the cooperati...
Citation: Journal of Hematology & Oncology 2023 16:23 -
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is accelerating. This analysis summarizes the data derived from the clinical trials conducted at MD Anderson between 1985 and 20...
Citation: Journal of Hematology & Oncology 2023 16:22 -
Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation
Despite mitochondrial DNA (mtDNA) mutations are common events in cancer, their global frequency and clinical impact have not been comprehensively characterized in patients with myelodysplastic neoplasia (also ...
Citation: Journal of Hematology & Oncology 2023 16:21 -
Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
Over one-third of B cell lymphomas are not effectively treated by R-CHOP chemotherapy. When lymphoma relapses or is refractory, the prognosis becomes very poor. Due to this fact, there is an urgent and clear r...
Citation: Journal of Hematology & Oncology 2023 16:20 -
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
TP53 mutations, which are present in 5% to 10% of patients with acute myeloid leukemia (AML), are associated with treatment resistance and poor outcomes. First-line therapies for TP53-mutated (TP53m) AML consist ...
Citation: Journal of Hematology & Oncology 2023 16:19 -
CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting
Due to the concern of fratricide, clinical development of CAR T cells for the therapy of T cell malignancies lags behind that for B cell malignancies. Attempts are being made to revise T cell biomarkers so tha...
Citation: Journal of Hematology & Oncology 2023 16:18 -
Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting
Developments in investigational agents and novel regimens in acute myeloid leukemia (AML) were reported in the 2022 American Society of Hematology (ASH) annual meeting. Encouraging efficacy data were presented...
Citation: Journal of Hematology & Oncology 2023 16:17 -
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain
The immunoglobulin J chain (Jchain) is highly expressed in the majority of multiple myeloma (MM), and Jchain-derived peptides presented in HLA molecules may be suitable antigens for T-cell therapy of MM.
Citation: Journal of Hematology & Oncology 2023 16:16 -
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia
The acute myeloid leukemia (AML) patients obtain limited benefits from current immune checkpoint blockades (ICBs), although immunotherapy have achieved encouraging success in numerous cancers. Here, we found t...
Citation: Journal of Hematology & Oncology 2023 16:15 -
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis
Citation: Journal of Hematology & Oncology 2023 16:14 -
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Citation: Journal of Hematology & Oncology 2023 16:13 -
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis
Citation: Journal of Hematology & Oncology 2023 16:12 -
Correction: SELP Asp603Asn and severe thrombosis in COVID-19 males
Citation: Journal of Hematology & Oncology 2023 16:11 -
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT
The association between graft-versus-host disease (GVHD) occurrence and acute myeloid leukemia (AML) relapse in patients treated with HLA-haploidentical allogeneic hematopoietic stem cell transplantation (Hapl...
Citation: Journal of Hematology & Oncology 2023 16:10 -
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
Selectively targeting leukemia stem cells (LSCs) is a promising approach in treating acute myeloid leukemia (AML), for which identification of such therapeutic targets is critical. Increasing lines of evidence...
Citation: Journal of Hematology & Oncology 2023 16:9 -
Exploiting RIG-I-like receptor pathway for cancer immunotherapy
RIG-I-like receptors (RLRs) are intracellular pattern recognition receptors that detect viral or bacterial infection and induce host innate immune responses. The RLRs family comprises retinoic acid-inducible g...
Citation: Journal of Hematology & Oncology 2023 16:8 -
Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma
The prognosis of pancreatic ductal adenocarcinoma (PDAC) is one of the most dismal of all cancers and the median survival of PDAC patients is only 6–8 months after diagnosis. While decades of research effort h...
Citation: Journal of Hematology & Oncology 2023 16:7 -
Protein degradation: expanding the toolbox to restrain cancer drug resistance
Despite significant progress in clinical management, drug resistance remains a major obstacle. Recent research based on protein degradation to restrain drug resistance has attracted wide attention, and several...
Citation: Journal of Hematology & Oncology 2023 16:6 -
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
T cell receptor (TCR)-T cells possess similar effector function, but milder and more durable signal activation compared with chimeric antigen receptor-T cells. TCR-T cell therapy is another active field of cel...
Citation: Journal of Hematology & Oncology 2023 16:5 -
How we treat primary immune thrombocytopenia in adults
Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder characterized by decreased platelet counts and an increased risk of bleeding. Multiple humoral and cellular immune abnormalities re...
Citation: Journal of Hematology & Oncology 2023 16:4 -
Payload diversification: a key step in the development of antibody–drug conjugates
Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that currently combines the selectivity of monoclonal antibodies with the potency of a payload consisting of cytotoxic agents....
Citation: Journal of Hematology & Oncology 2023 16:3 -
A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety
The antiphagocytic molecule CD47 is overexpressed in a wide variety of cancer cells, and antibodies targeting CD47 for cancer therapies are currently under intensive investigation. However, owing to the ubiqui...
Citation: Journal of Hematology & Oncology 2023 16:2
-
Official journal of
-
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Instructions for authors
- Sign up for article alerts and news from this journal
Follow
Annual Journal Metrics
-
2022 Citation Impact
28.5 - 2-year Impact Factor
23.1 - 5-year Impact Factor
4.045 - SNIP (Source Normalized Impact per Paper)
6.046 - SJR (SCImago Journal Rank)2023 Speed
5 days submission to first editorial decision for all manuscripts (Median)
59 days submission to accept (Median)2023 Usage
3,173,795 downloads
2,671 Altmetric mentions
On the blog
-
-
Winners of the 2022 Cardio-Oncology Journal Prize
06 April 2023
-
Institutional membership
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).